I-Mab | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (9)

View All

Latest Posts

About This Stock More About This Stock
Week In Review: GenFleet Out-Licenses Three Candidates To Verastem In $625 Million Deal
Article By: ChinaBio® Today
Saturday, September 2, 2023 1:59 PM EDT
Shanghai GenFleet Technologies partnered three preclinical small-molecule candidates for RAS pathway-driven cancers to Verastem Oncology in a deal that could be worth up to $625.5 million. GenFleet will receive an initial payment of $11.5 million.
In this article: VSTM Also: BNTX, IMAB
Read
Week In Review: METiS, A US-China AI Biotech, Acquires Pan-RAF Inhibitor In $482 Million Deal
Article By: ChinaBio® Today
Saturday, September 17, 2022 1:20 PM EDT
METiS Therapeutics in-licensed global rights to a pan-RAF inhibitor program from Korea’s Voronoi in a deal worth up to $482 million. METiS will pay only $1.7 million upfront, with provision for $480.5 million in milestone payments, plus royalties.
In this article: 300003.SZ, IMAB, JMAC, 2157.HK, 2196.HK, 6821.HK
Read
Week In Review: Biocytogen, A Genetically Modified Animal Models Company, Stages $60 Million IPO
Article By: ChinaBio® Today
Saturday, September 3, 2022 3:51 PM EDT
Beijing Biocytogen Pharma completed a $60 million IPO on the Hong Kong Exchange for its genetically modified animal and cell model business, which it offers to pharmaceutical/biotech companies. Biocytogen has a market capitalization of $357 million. 
In this article: 2315.HK Also: JNJ, ACOR, IMAB, 300558.SZ, 2257.HK
Read
Week In Review: China And The US May Settle De-Listing/Accounting Impasse
Article By: ChinaBio® Today
Saturday, August 27, 2022 2:20 PM EDT
China and the US are close to solving the accounting rules crisis that threatens to de-list 261 China companies from US exchanges. The list of affected biopharma companies includes BeiGene, Legend Bio, Zai Labs, and many more.
In this article: AZN, WINT, IMAB, 0950.HK, 3692.HK, 2197.HK, 2257.HK
Read
Week In Review: Joincare Plans $300-$400 Million IPO On Swiss Exchange
Article By: ChinaBio® Today
Saturday, June 18, 2022 1:19 PM EDT
Joincare Pharmaceutical of Shenzhen plans to list on the SIX Swiss stock exchange, an unusual venue for a China biopharma. The company said it aims to broaden its financing sources and increase global expansion.
In this article: 1228.HK, 600380.SS, IMAB, OGN, 2696.HK, 9966.HK, 2197.HK, MOR, QNRX
Read
All Posts

Latest Tweets for $IMAB

No tweets yet!

PARTNER HEADLINES